Integra Long Term Debt vs Long Term Debt Total Analysis

IART Stock  USD 24.18  0.08  0.33%   
Integra LifeSciences financial indicator trend analysis is infinitely more than just investigating Integra LifeSciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Integra LifeSciences is a good investment. Please check the relationship between Integra LifeSciences Long Term Debt and its Long Term Debt Total accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Long Term Debt vs Long Term Debt Total

Long Term Debt vs Long Term Debt Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Integra LifeSciences Long Term Debt account and Long Term Debt Total. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Integra LifeSciences' Long Term Debt and Long Term Debt Total is 0.92. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Long Term Debt Total in the same time period over historical financial statements of Integra LifeSciences Holdings, assuming nothing else is changed. The correlation between historical values of Integra LifeSciences' Long Term Debt and Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Integra LifeSciences Holdings are associated (or correlated) with its Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt Total has no effect on the direction of Long Term Debt i.e., Integra LifeSciences' Long Term Debt and Long Term Debt Total go up and down completely randomly.

Correlation Coefficient

0.92
Relationship DirectionPositive 
Relationship StrengthVery Strong

Long Term Debt

Long-term debt is a debt that Integra LifeSciences has held for over one year. Long-term debt appears on Integra LifeSciences Holdings balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Integra LifeSciences Holdings balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Long Term Debt Total

Most indicators from Integra LifeSciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Integra LifeSciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
At this time, Integra LifeSciences' Selling General Administrative is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 0.57 in 2025, whereas Enterprise Value Over EBITDA is likely to drop 10.86 in 2025.
 2022 2023 2024 2025 (projected)
Gross Profit970.3M888.4M1.0B1.1B
Total Revenue1.6B1.5B1.8B1.9B

Integra LifeSciences fundamental ratios Correlations

0.970.960.980.950.950.860.880.811.0-0.20.840.970.80.990.940.770.720.990.880.970.970.980.830.76-0.01
0.970.970.920.890.960.780.840.770.97-0.020.80.950.80.980.920.770.720.980.80.940.970.980.810.69-0.02
0.960.970.910.870.940.740.850.830.95-0.150.840.930.780.960.870.850.760.970.750.950.950.980.830.64-0.04
0.980.920.910.960.870.890.850.840.97-0.270.870.940.790.930.930.730.730.940.90.970.930.920.810.770.01
0.950.890.870.960.870.940.890.750.94-0.190.790.920.710.920.970.650.580.920.950.930.880.90.730.82-0.03
0.950.960.940.870.870.750.90.640.96-0.060.670.960.750.980.90.710.640.980.770.870.970.980.780.66-0.06
0.860.780.740.890.940.750.770.750.84-0.250.80.790.540.830.90.60.350.820.980.880.750.810.580.91-0.12
0.880.840.850.850.890.90.770.580.9-0.240.610.940.680.880.880.540.590.880.790.810.870.880.710.58-0.17
0.810.770.830.840.750.640.750.580.77-0.381.00.690.60.760.680.80.630.770.740.90.730.770.690.680.01
1.00.970.950.970.940.960.840.90.77-0.190.80.970.80.990.940.730.720.990.870.940.990.980.830.740.0
-0.2-0.02-0.15-0.27-0.19-0.06-0.25-0.24-0.38-0.19-0.35-0.16-0.14-0.14-0.07-0.16-0.2-0.14-0.24-0.23-0.18-0.14-0.21-0.110.01
0.840.80.840.870.790.670.80.611.00.8-0.350.710.60.790.730.80.610.80.790.920.750.80.690.740.0
0.970.950.930.940.920.960.790.940.690.97-0.160.710.830.960.940.690.730.960.80.910.960.960.820.63-0.02
0.80.80.780.790.710.750.540.680.60.8-0.140.60.830.770.770.60.860.780.550.760.810.760.90.360.24
0.990.980.960.930.920.980.830.880.760.99-0.140.790.960.770.930.750.671.00.850.940.981.00.810.74-0.02
0.940.920.870.930.970.90.90.880.680.94-0.070.730.940.770.930.650.560.930.890.920.890.910.720.75-0.03
0.770.770.850.730.650.710.60.540.80.73-0.160.80.690.60.750.650.620.770.540.840.710.780.650.6-0.02
0.720.720.760.730.580.640.350.590.630.72-0.20.610.730.860.670.560.620.690.390.680.770.690.880.240.2
0.990.980.970.940.920.980.820.880.770.99-0.140.80.960.781.00.930.770.690.840.940.981.00.820.73-0.02
0.880.80.750.90.950.770.980.790.740.87-0.240.790.80.550.850.890.540.390.840.870.790.820.610.91-0.09
0.970.940.950.970.930.870.880.810.90.94-0.230.920.910.760.940.920.840.680.940.870.90.940.780.77-0.03
0.970.970.950.930.880.970.750.870.730.99-0.180.750.960.810.980.890.710.770.980.790.90.980.850.650.02
0.980.980.980.920.90.980.810.880.770.98-0.140.80.960.761.00.910.780.691.00.820.940.980.810.71-0.05
0.830.810.830.810.730.780.580.710.690.83-0.210.690.820.90.810.720.650.880.820.610.780.850.810.490.26
0.760.690.640.770.820.660.910.580.680.74-0.110.740.630.360.740.750.60.240.730.910.770.650.710.49-0.12
-0.01-0.02-0.040.01-0.03-0.06-0.12-0.170.010.00.010.0-0.020.24-0.02-0.03-0.020.2-0.02-0.09-0.030.02-0.050.26-0.12
Click cells to compare fundamentals

Integra LifeSciences Account Relationship Matchups

Integra LifeSciences fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets3.6B3.8B3.9B3.8B4.3B4.6B
Other Current Liab182.1M198.3M144.2M176.3M202.7M212.9M
Total Current Liabilities401.0M340.0M320.9M307.0M353.0M370.7M
Total Stockholder Equity1.5B1.7B1.8B1.6B1.8B1.9B
Property Plant And Equipment Net371.2M396.2M459.6M496.4M570.8M599.4M
Net Debt1.2B1.1B1.2B1.4B1.6B1.7B
Retained Earnings532.3M698.6M879.1M946.9M1.1B1.1B
Accounts Payable54.6M61.8M102.1M92.3M106.2M111.5M
Cash470.2M513.4M456.7M276.4M317.9M333.8M
Non Current Assets Total2.4B2.6B2.7B2.7B3.1B3.3B
Non Currrent Assets Other11.3M10.0M(510.2M)27.5M24.7M26.0M
Cash And Short Term Investments470.2M513.4M456.7M309.1M355.5M373.2M
Net Receivables225.5M231.8M263.5M259.3M298.2M313.1M
Common Stock Shares Outstanding85.2M85.5M83.5M80.3M92.4M67.2M
Liabilities And Stockholders Equity3.6B3.8B3.9B3.8B4.3B4.6B
Non Current Liabilities Total1.7B1.8B1.8B1.9B2.2B2.3B
Inventory310.1M317.4M324.6M389.6M448.0M470.5M
Other Current Assets231.4M91.1M116.8M100.0M115.0M120.8M
Other Stockholder Equity1.1B1.0B914.1M655.2M753.5M467.2M
Total Liab2.1B2.1B2.1B2.2B2.5B2.6B
Property Plant And Equipment Gross371.2M711.1M789.3M863.8M993.4M1.0B
Total Current Assets1.2B1.2B1.2B1.1B1.2B1.3B
Accumulated Other Comprehensive Income(74.1M)(45.2M)10.3M(15.1M)(13.6M)(14.3M)
Intangible Assets989.4M1.1B1.1B1.1B1.2B1.3B
Short Long Term Debt Total1.7B1.7B1.6B1.7B1.9B2.0B
Common Stock Total Equity887K893K896K905K1.0M528.7K
Short Term Investments4.7M12K16.7M32.7M29.4M30.9M
Short Term Debt159.1M74.6M67.4M29.8M34.3M32.6M
Common Stock893K896K905K909K1.0M547.5K
Other Liab116.1M131.2M135.9M201.8M232.1M243.7M
Other Assets27.3M168.6M3.8B63.2M72.6M69.0M
Long Term Debt1.4B1.4B1.3B1.5B1.7B1.8B
Treasury Stock(119.9M)(235.1M)(234.4M)(362.9M)(326.6M)(310.2M)
Property Plant Equipment337.4M287.5M311.7M311.3M358.0M375.9M
Current Deferred Revenue5.3M5.3M7.3M8.5M9.8M5.3M
Good Will932.4M1.0B1.0B1.1B1.2B1.3B
Net Tangible Assets(569.1M)(406.9M)(474.2M)(361.1M)(325.0M)(341.2M)
Retained Earnings Total Equity398.6M532.3M698.6M879.1M1.0B1.1B
Long Term Debt Total1.2B1.4B1.4B1.3B1.5B1.0B
Capital Surpluse1.2B1.3B1.3B1.3B1.5B1.0B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Integra Stock Analysis

When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.